Repro Biotech Completes Tens of Millions RMB Series A Financing to Accelerate Full-Line Layout of Assisted Reproductive Technology Devices

VCBeat (WeChat ID: vcbeat) has learned that Reprobiotech Corp China Ltd. (hereinafter referred to as “Reprobiotech”) recently announced the completion of its Series A financing round, amounting to tens of millions of yuan.Led by Chongqing Dianshi Chuangjian Fund, with follow-on investments from Shanghai Jianmu Investment and Shanghai Chuangrui Investment; Index Capital served as the exclusive financial advisor.. The proceeds from the financing will be used for the construction of the company's research centers, product registration, market promotion, and other aspects.

Reprobiotech, established in 2016, is a medical device supplier deeply engaged in the research and development of upstream reagents and consumables for assisted reproduction, committed to creating comprehensive high-quality embryo culture system solutions. Since its inception, the company has focused on the commercialization of a full range of assisted reproductive products. Guided by design principles of naturalization, simplification, and safety, it has facilitated the market translation of more than 30 specialized medical devices for assisted reproduction, forming four major product lines: the “Oocyte Series,” “Sperm Series,” “Embryo Culture Series,” and “Cryopreservation and Thawing Series.”

In addition to product commercialization, Reprobiotech has repeatedly participated in the formulation of industry standards for assisted reproduction. Its proposal on “Promoting the Localization of Assisted Reproduction Products” received direct instructions from leaders of the National Medical Products Administration (NMPA), endorsing the approval and market launch of domestically produced brands.

Since the birth of China’s first test-tube baby in 1988, assisted reproductive technology (ART) treatment has undergone substantial development over more than three decades. However, the domestic upstream market for reagents and consumables remains nearly vacant. The upstream medical device market for ART in China has long been monopolized by imported brands. Due to a lack of core technologies, certain ART reagents and consumables are heavily reliant on imports. Should the supply of these imported products be disrupted, hundreds of downstream ART centers across China would face a critical shortage of embryo culture media—akin to “embryo weaning”—thereby constraining the independent development of China’s ART industry.

In light of this situation, the primary task for domestic manufacturers of ART medical devices is to achieve import substitution as early as possible, enabling more than 500 assisted reproductive technology centers downstream in China to choose domestically branded device products and support the localization of product development.

Meanwhile, for domestic brands to replace imported products, it is not enough for their performance and quality to merely match those of imports; they must also develop ART devices specifically tailored for the treatment of local Chinese patients. This is the original aspiration that drives Reprobiotech Corp China Ltd to focus on the comprehensive commercialization of its assisted reproductive technology product portfolio.

To advance the localization of assisted reproductive technology (ART) medical devices, Reprobiotech Corp China Ltd., a leading enterprise in the industry, is accelerating the NMPA registration of more than 20 products. It has already obtained NMPA registration certification for 13 ART medical device products (11 Class II and 2 Class III medical devices).

Reprobiotech’s independently developed “Oocyte Retrieval Fluid"As the first domestically produced product to achieve a 'zero breakthrough' in the assisted reproductive technology industry, it is used for oocyte retrieval and (follicular) flushing procedures, as well as for gamete incubation. It holds the first domestic liquid registration certificate, which was obtained in May 2020."

Independently developed “Vitrification Cryoloop”designed based on the carrier and fluid dynamics at the liquid surface (similar to lotus leaves and water), achieving non-adhesion and no loss of embryos, maintaining the integrity of embryonic DNA. Extensive experimental data have proven its effectiveness in significantly improving implantation rates.

"Independently developed, market-unique product"One-Step Culture Medium"It can replace sequential culture media; once launched, it will significantly simplify the operational procedures and product variety of ART culture systems, streamline culture operations, and achieve higher rates of high-quality blastocysts."

All product designs developed by the company are built upon years of scientific research and clinical study outcomes, guided by the philosophy of simpler operation, enhanced safety, and more natural fertilization. By employing scientifically formulated designs, high-cleanliness production environments, and stable manufacturing processes, we strive to achieve optimal clinical performance.

It is worth noting that, as of now, there have already beenOver 100 Domestic Reproductive CentersReprobiotech Corp China Ltd has officially procured its ART products, demonstrating a tangible commitment to the domestic substitution of imported goods.

Regarding the investment in Reprobiotech,Dr. Zhang Minglong, Deputy General Manager of Chongqing Dianshi Chuangjian Fund and Partner at Shanghai Chuangrui Investment ManagementStated: “Chongqing Dianshi Chuangjian and Shanghai Chuangrui Investment focus on investing in advanced domestic medical technologies, promoting the localization, widespread adoption, and technological upgrading of high-end medical products. The global infertility rate is increasing year by year, making fertility a worldwide challenge! China’s infertility rate has reached 17%, with over 15 million families struggling to conceive. Assisted Reproductive Technology (ART) is currently the best solution for infertility; however, compared to the 31% penetration rate in the United States, China’s stands at only 8%, indicating a potential market size of RMB 400 billion. We are highly optimistic about this sector, as it aligns with long-term population policies in both China and globally, as well as the rigid demand from customers.”

Reprobiotech Corp China Ltd industrializes globally leading technologies developed by top-tier international clinical expert teams in China, ensuring its products better align with clinical practices and requirements. The company has obtained registration certificates for 13 products, many of which are the first domestically produced equivalents, and these have been adopted by over 100 assisted reproductive technology (ART) centers. In the next two years, more than 10 new products are expected to receive registration approval, establishing a comprehensive product portfolio of ART consumables and reagents—spanning the “Oocyte Series,” “Sperm Series,” “Embryo Culture Series,” and “Cryopreservation/Thawing Series”—and providing one-stop solutions.

“We are honored to partner with Reprobiotech Corp China Ltd. to jointly build an international brand for assisted reproductive consumables and reagents, providing high-quality products and services to over 40 million infertile couples and medical institutions in China, thereby promoting fertility in China and globally, and bringing the gospel of accessibility to life!”

Regarding the investment in Reprobiotech,Jianmu InvestmentA company representative stated, “Reprobiotech’s product development is driven by a global team of top-tier experts with clinical backgrounds, enabling the company to accumulate substantial technological expertise and fully possess the potential and capability to replace imported products. With the most comprehensive product portfolio in the industry and offerings tailored to the Chinese market, Reprobiotech has established significant competitive barriers and emerged as a leading enterprise in the first tier of the sector. We believe that Reprobiotech Corp China Ltd will effectively reduce China’s reliance on imported devices in assisted reproductive technology, bringing ‘new life’ to millions of families struggling with infertility.”

Chongqing Dianshi Chuangjian Fund Management Company was established in 2016. Guided by the core philosophy of leading the upgrading of China’s healthcare industry, it is an institution focused on investing in high-end medical technology and related industries in China. Its Phase I fund was jointly capitalized by Chongqing Huayi Xintian Investment, Chongqing Industrial Guidance Fund, Chongqing Science & Technology Venture Capital, Chongqing Linkong Investment, and other institutions. The company’s portfolio covers areas such as in vitro diagnostics, high-end imaging, cardiovascular care, orthopedics, genetic testing, and artificial intelligence. Half of its invested companies have entered the pre-IPO tutoring phase, and all have secured subsequent rounds of financing.

In August 2020, Dianshi Chuangjian was honored with the “Financing China 2019–2020 Best Early-Stage Investment Institution in China’s Healthcare Industry” award; in April 2021, it ranked among the Top 5 Emerging Healthcare Investment Institutions in VCBeat’s 2020–2021 Future Healthcare 100 “Pengcheng Awards.”

Jianmu (Shanghai) Investment Management Co., Ltd. is a professional fund management company specializing in equity investments in forward-looking and strategic emerging sectors, as well as the management of funds of funds (FOFs). The company operates on a core model integrating “industry funds,” “technology transfer and incubation platforms,” and “industrial parks.” By leveraging its FOF advantages, it builds an industrial investment platform through a cluster of sub-funds, achieving amplification in capital, information, resources, and outcomes. Its fund investments span multiple regions, industries, and stages, having invested in over 100 outstanding enterprises across sectors such as intelligent manufacturing, medical devices/biopharmaceuticals, new energy vehicles, consumer/service industries, and smart logistics.

Shanghai Chuangrui Investment Group was officially established in 2009. As an investment firm integrating equity investment with the incubation of advanced medical industries, it is committed to investing in global high-end medical technologies and upholding the core philosophy of leading the upgrading of China’s healthcare industry. Chuangrui Fund manages assets exceeding RMB 3 billion and has invested in nearly 40 companies both domestically and internationally. As of June 2021, eight of its portfolio companies had successfully gone public, while seven others were queued for listing review.

Selected Success Stories of Chuangrui Investment: Wolwo Bio-Pharma (listed), Jianan Pharmaceutical Machinery (listed), Rundu Pharmaceutical (listed), Mingfeng Medical (China’s first manufacturer of 256-slice CT scanners), Akeso Biopharma (listed, an innovative drug developer), Tiansong Medical (a leading endoscopy company), Kehui Medical (an orthopedic consumables company), and Lanyi Technology (an IVD company).

Meanwhile, Chuangrui has formed partnerships with renowned domestic and international medical institutions, including Cleveland Clinic in the United States, Stanford Hospital in the United States, Maccabi Healthcare Services in Israel, Chongqing Medical University, and Chengdu University of Traditional Chinese Medicine, to jointly establish an official platform for the commercialization of scientific and technological achievements.